Related Experiment Video

Updated: May 22, 2026

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
12:16

Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma

Published on: March 13, 2013

CD133 negatively regulates tumorigenicity via AKT pathway in synovial sarcoma

Taichi Kimura1, Lei Wang, Kouichi Tabu

  • 1Department of Pathology, Laboratory of Cancer Research, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Cancer Investigation
|May 11, 2012
PubMed

Insights

CD133 expression negatively impacts synovial sarcoma (SS) cell growth by inhibiting the AKT signaling pathway. Targeting AKT can suppress the proliferation of CD133-negative SS cells, offering potential therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Synovial sarcoma (SS) is an aggressive soft tissue sarcoma, comprising nearly 10% of all such tumors.
  • The role of CD133 in SS pathogenesis and progression remains incompletely understood.
  • Identifying key molecular drivers is crucial for developing targeted therapies for SS.

Purpose of the Study:

  • To investigate the functional role of CD133 in synovial sarcoma.
  • To elucidate the signaling pathways influenced by CD133 expression in SS cells.
  • To explore the therapeutic potential of targeting CD133-associated pathways.

Main Methods:

  • Expression analysis of CD133 in human SS specimens.
  • Separation of CD133-positive and CD133-negative subpopulations from SS cell lines.
  • Assessment of cell proliferation and AKT phosphorylation in separated subpopulations.
  • Evaluation of the effect of an AKT inhibitor on cell growth.

Main Results:

  • CD133 expression was detected in human SS specimens.
  • CD133-negative SS cells demonstrated enhanced proliferation and AKT hyperphosphorylation compared to CD133-positive cells.
  • Inhibition of AKT significantly reduced the growth of CD133-negative SS cells to levels comparable to CD133-positive cells.

Conclusions:

  • CD133 negatively regulates SS cell growth.
  • The AKT signaling pathway is implicated in CD133-mediated growth control in SS.
  • Targeting the AKT pathway presents a potential therapeutic strategy for synovial sarcoma, particularly in CD133-negative tumors.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...